Cantor Fitzgerald Brokers Lift Earnings Estimates for Cerus

Cerus Co. (NASDAQ:CERS) – Equities research analysts at Cantor Fitzgerald raised their FY2024 earnings per share estimates for Cerus in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now expects that the biotechnology company will post earnings per share of ($0.11) for the year, up from their previous estimate of ($0.12). The consensus estimate for Cerus’ current full-year earnings is ($0.12) per share. Cantor Fitzgerald also issued estimates for Cerus’ FY2025 earnings at ($0.06) EPS.

Cerus (NASDAQ:CERS) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. The company had revenue of $46.02 million during the quarter, compared to analysts’ expectations of $44.10 million. Cerus had a negative net margin of 11.19% and a negative return on equity of 37.90%. During the same period in the previous year, the company earned ($0.03) EPS.

Separately, Stifel Nicolaus cut their price objective on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, October 17th.

Cerus Stock Performance

CERS opened at $1.81 on Thursday. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The business’s fifty day simple moving average is $1.71 and its 200-day simple moving average is $1.89. Cerus has a 12-month low of $1.38 and a 12-month high of $2.59.

Insider Activity at Cerus

In other news, Director Eric Bjerkholt sold 20,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $1.78, for a total transaction of $35,600.00. Following the transaction, the director now owns 162,133 shares in the company, valued at $288,596.74. This represents a 10.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Cerus

Large investors have recently bought and sold shares of the stock. Easterly Investment Partners LLC raised its position in Cerus by 726.1% during the 3rd quarter. Easterly Investment Partners LLC now owns 313,522 shares of the biotechnology company’s stock worth $546,000 after buying an additional 275,569 shares during the last quarter. Bouvel Investment Partners LLC raised its holdings in shares of Cerus by 87.1% during the third quarter. Bouvel Investment Partners LLC now owns 505,020 shares of the biotechnology company’s stock worth $879,000 after purchasing an additional 235,082 shares during the last quarter. Sei Investments Co. lifted its position in Cerus by 658.9% during the second quarter. Sei Investments Co. now owns 263,839 shares of the biotechnology company’s stock valued at $464,000 after purchasing an additional 229,074 shares during the period. Barclays PLC grew its position in Cerus by 16.2% during the 3rd quarter. Barclays PLC now owns 1,575,049 shares of the biotechnology company’s stock worth $2,740,000 after purchasing an additional 219,755 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Cerus during the 3rd quarter valued at about $353,000. Hedge funds and other institutional investors own 78.37% of the company’s stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.